Eribulin Bone Merastasis Complete Recovery
https://www.karger.com/Article/FullText/489061
Long-Term Response with Eribulin Mesylate in a Breast Cancer Patient: A Case Report.
Medici M. · Fossile E.
Oncology 2018;94(suppl 1):3–5
In December 2015, PET and MRI showed focal hyperaccumulation at the spine and hips (Fig. 1). These lesions were associated with severe pain (8–10 on a visual analogical scale).
After multidisciplinary assessment of the case, given the refractoriness to prior regimens, the triple-negative status of the disease, the presence of severe pain, and the relatively young age of the patient, we instituted therapy with eribulin mesylate (1.23 mg/m2 on days 1 and 8, every 21-day cycle) in January 2016. This therapy was associated with palliative radiotherapy on bone lesions (3–30 Gy). In March 2016, the patient showed a partial response on bone lesions. In August 2016, US imaging showed liver steatosis, which was paralleled by increased transaminases. However, examination by a hepatology specialist excluded liver involvement and/or treatment-related toxicity. Further imaging examinations, in November 2016, showed a complete response (CR) at all lesions.
